Vanguard Group Inc. Sells 100,781 Shares of Illumina, Inc. (NASDAQ:ILMN)

Vanguard Group Inc. lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 0.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,813,419 shares of the life sciences company's stock after selling 100,781 shares during the quarter. Vanguard Group Inc. owned approximately 9.97% of Illumina worth $2,113,147,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the business. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new position in Illumina during the 4th quarter valued at about $32,000. Assetmark Inc. raised its holdings in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the fourth quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina during the 4th quarter worth $48,000. Institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research analyst reports. Barclays restated an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Guggenheim cut their price objective on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Stephens reissued an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Royal Bank of Canada lowered their target price on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 12th. Finally, Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

Remove Ads

Illumina Stock Down 1.2 %

Shares of ILMN traded down $0.94 on Monday, hitting $79.06. The company's stock had a trading volume of 368,308 shares, compared to its average volume of 2,204,805. The firm has a market capitalization of $12.52 billion, a price-to-earnings ratio of -10.30, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a fifty-two week low of $77.65 and a fifty-two week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm's fifty day moving average price is $102.80 and its 200-day moving average price is $126.82.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.